Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Xelevia opvejer risiciene ved behandling af patienter med type 2 diabetes mellitus til forbedring af den glykæmiske kontrol i kombination med metformin og/ eller et sulfonylurinstof eller en PPAR- gammaagonist, når diæt og motion samt de andre lægemidler ikke giver tilfredsstillende glykæmisk kontrol.
The Committee for Medicinal Products for Human Use (CHMP) decided that Xelevia’ s benefits are greater than its risks for the treatment of patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin and/ or a sulphonylurea, or a PPAR gamma agonist, when diet and exercise plus the other medicines do not provide adequate glycaemic control.